News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,922 Results
Type
Article (39705)
Company Profile (248)
Press Release (658969)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204196)
Career Advice (2007)
Deals (35425)
Drug Delivery (95)
Drug Development (81053)
Employer Resources (172)
FDA (16180)
Job Trends (14859)
News (345221)
Policy (32538)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49437)
ALS (88)
Alzheimer's disease (1379)
Antibody-drug conjugate (ADC) (124)
Approvals (16185)
Artificial intelligence (254)
Autoimmune disease (21)
Automation (16)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (175)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (278)
Cancer (2259)
Cardiovascular disease (174)
Career advice (1676)
Career pathing (30)
CAR-T (151)
Cell therapy (423)
Cervical cancer (19)
Clinical research (65991)
Collaboration (832)
Company closure (1)
Compensation (533)
Complete response letters (19)
COVID-19 (2588)
CRISPR (40)
C-suite (241)
Cystic fibrosis (100)
Data (2205)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (270)
Diagnostics (6370)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (99)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86639)
Editorial (37)
Employer branding (21)
Employer resources (146)
Events (112429)
Executive appointments (722)
FDA (17443)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (748)
Gene editing (104)
Generative AI (19)
Gene therapy (302)
GLP-1 (709)
Government (4416)
Grass and pollen (4)
Guidances (67)
Healthcare (18814)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (115)
Indications (29)
Infectious disease (2730)
Inflammatory bowel disease (137)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16511)
IRA (40)
Job creations (3631)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (468)
Leadership (17)
Legal (7909)
Liver cancer (75)
Lung cancer (320)
Lymphoma (154)
Machine learning (7)
Management (58)
Manufacturing (304)
MASH (67)
Medical device (13379)
Medtech (13384)
Mergers & acquisitions (19457)
Metabolic disorders (685)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1914)
NextGen: Class of 2025 (6517)
Non-profit (4480)
Now hiring (39)
Obesity (364)
Opinion (204)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (112)
Peanut (46)
People (57307)
Pharmaceutical (64)
Pharmacy benefit managers (18)
Phase I (20561)
Phase II (29059)
Phase III (21649)
Pipeline (1203)
Policy (139)
Postmarket research (2563)
Preclinical (8740)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5907)
Recruiting (65)
Regulatory (22282)
Reports (46)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (69)
Series A (130)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3588)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (40)
The Weekly (29)
Vaccines (689)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (140)
Last 7 days (897)
Last 30 days (2622)
Last 365 days (32699)
2025 (10736)
2024 (35221)
2023 (40078)
2022 (51173)
2021 (55715)
2020 (54085)
2019 (46538)
2018 (35021)
2017 (32114)
2016 (31482)
2015 (37555)
2014 (31322)
2013 (26350)
2012 (28576)
2011 (29269)
2010 (27336)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (37852)
Australia (6184)
California (6135)
Canada (2017)
China (523)
Colorado (266)
Connecticut (274)
Delaware (148)
Europe (81267)
Florida (912)
Georgia (206)
Idaho (57)
Illinois (536)
India (25)
Indiana (308)
Iowa (11)
Japan (162)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (894)
Massachusetts (4568)
Michigan (220)
Minnesota (391)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1727)
New Mexico (28)
New York (1746)
North Carolina (968)
North Dakota (8)
Northern California (2682)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1377)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (23)
South Dakota (1)
Southern California (2304)
Tennessee (101)
Texas (907)
United States (23128)
Utah (180)
Virginia (146)
Washington D.C. (62)
Washington State (551)
West Virginia (3)
Wisconsin (54)
698,922 Results for "bioventures inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Capital BioVentures Announces Inaugural Cohort for Ottawa Biotech Accelerator Program
December 3, 2024
·
6 min read
BioMidwest
NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease
NephroDI Therapeutics (NephroDI), a near-clinical stage pharmaceutical company focusing on kidney disorders, announces a Series A investment from life sciences VC Sound Bioventures.
June 20, 2024
·
4 min read
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics
Sound Bioventures announced a new investment in Theolytics, a UK biotechnology company developing next-generation oncolytic viral therapies.
April 17, 2024
·
4 min read
Press Releases
Arrivo BioVentures Announces Positive Results from qEEG and BNA™ Study of SP-624 on Neural Brain Activity Related to Depression and Cognition
January 10, 2025
·
4 min read
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, announced it has successfully closed its latest financing round, raising a total of £19M with the addition of Sound Bioventures as a new investor.
April 17, 2024
·
4 min read
Pharm Country
Harmonic Discovery Announces Licensing Agreement with BioVentures and UCSF for FLT3 Mutated AML Development Program
Harmonic Discovery announced an exclusive licensing agreement of a novel small-molecule drug candidate for the treatment of FLT3 mutated acute myeloid leukemia from BioVentures and UC San Francisco.
January 30, 2024
·
3 min read
Press Releases
Arrivo BioVentures Begins Phase 1 Study of SP-624, the First Potential Treatment Specifically for Women with Major Depressive Disorder
October 10, 2024
·
3 min read
Press Releases
Altius Bioventures Launches The CGT Industry Atlas, Mapping out the Cell and Gene Therapy Technology Innovation Landscape
September 11, 2024
·
2 min read
Policy
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
Alvotech and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC, announced that the Egyptian Drug Authority has approved the manufacturing and distribution of AVT02 a biosimilar for Humira®, which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases, under the trade name Adalimumab-EVA™.
August 29, 2023
·
10 min read
Business
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
G1 Therapeutics, Inc., a commercial-stage oncology company, and Deimos Biosciences, a portfolio company of Jupiter Bioventures, announced a global licensing agreement for lerociclib for radioprotective uses.
May 22, 2024
·
5 min read
1 of 69,893
Next
